Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25771498 | 0.86 | KMO (0.59) | KMOPIK3CAPKMHTTRAB9A | |
| SCHEMBL14558281 | 0.82 | WNT1 (0.49) | PKMRAB9AALDH1A1PPARGL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5343724 | 0.81 | WNT1 (0.48) | PKMRAB9AALDH1A1PPARGL3MBTL1 | |
| SCHEMBL25771496 | 0.80 | KMO (0.52) | KMOPIK3CAPKMRAB9APOLB | |
| SCHEMBL17075517 | 0.79 | ALDH1A1 (0.57) | KMOPIK3CAPKMHTTSMN1; SMN2 | |
| SCHEMBL15923518 | 0.79 | KMO (0.51) | KMOPIK3CAPKMSMN1; SMN2POLB | |
| SCHEMBL25771504 | 0.78 | KMO (0.50) | KMOPIK3CAPKMRAB9APOLB | |
| SCHEMBL15054582 | 0.78 | MAPT (0.66) | KMOPIK3CAPKMSMN1; SMN2RAB9A | |
| SCHEMBL30989601 | 0.76 | KMO (0.51) | KMOPIK3CAPKMHTTPOLB | |
| SCHEMBL21246773 | 0.75 | CNR2 (0.52) | PIK3CASMN1; SMN2CNR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | KMO 690/4885PIK3CA 803/4885PKM 763/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | KMO 690/4885PIK3CA 803/4885PKM 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.